Deadline Alert: Bronstein, Gewirtz & Grossman, LLC Reminds Veru Inc. (VERU) Investors of Class Action and to Actively Participate
Deadline Alert: Bronstein, Gewirtz & Grossman, LLC Reminds Veru Inc. (VERU) Investors of Class Action and to Actively Participate
New York, New York--(Newsfile Corp. - February 3, 2023) - Bronstein, Gewirtz & Grossman, LLC notifies investors that a class action lawsuit has been filed against Veru Inc. ("Veru" or the "Company") (NASDAQ: VERU) and certain of its officers, on behalf of all persons and entities that purchased, or otherwise acquired Veru common stock during the period from May 11, 2022 to November 9, 2022, inclusive (the "Class Period"). Such investors are encouraged to join this case by visiting the firm's site: .
纽约，纽约--（Newsfile Corp. ——2023年2月3日）——Bronstein、Gewirtz & Grossman, LLC通知投资者，已对Veru Inc提起集体诉讼。（“Veru” 或 “公司”）（纳斯达克股票代码：VERU）及其某些高管，代表在2022年5月11日至2022年11月9日（含 “集体诉讼期”）期间购买或以其他方式收购Veru普通股的所有个人和实体。鼓励此类投资者通过访问该公司的网站来加入此案:.
This class action seeks to recover damages against Defendants for alleged violations of the federal securities laws.
该集体诉讼旨在追回被告因涉嫌违反联邦证券法而遭受的损失。
The Complaint alleges that throughout the Class Period, Defendants made false and/or misleading statements, as well as failed to disclose material adverse facts about the data from the sabizabulin Phase 3 trial and the Company's interactions with the FDA. Specifically, Veru misled its shareholders to believe that the data from the Phase 3 trial was sufficient to support Emergency Use Authorization ("EUA") and even the submission of a New Drug Application ("NDA") without any further studies. VERU's filings therefore concealed the true risks faced by the Company in gaining approval for its EUA request.
申诉称，在整个集体诉讼期内，被告做出了虚假和/或误导性陈述，也没有披露有关sabizabulin第三阶段试验数据以及公司与FDA互动的重大不利事实。具体而言，Veru误导其股东相信3期试验的数据足以支持紧急使用授权（“EUA”），甚至无需进一步研究即可提交新药申请（“NDA”）。因此，VERU的文件掩盖了该公司在获得EUA申请批准时面临的真正风险。
A class action lawsuit has already been filed. If you wish to review a copy of the Complaint you can visit the firm's site: or you may contact Peretz Bronstein, Esq. or his Law Clerk and Client Relations Manager, Yael Nathanson of Bronstein, Gewirtz & Grossman, LLC at 212-697-6484. If you suffered a loss in Veru you have until February 6, 2023 to request that the Court appoint you as lead plaintiff. Your ability to share in any recovery doesn't require that you serve as a lead plaintiff.
已经提起了集体诉讼。如果您想查看投诉的副本，可以访问该公司的网站：或者您可以致电212-697-6484与Peretz Bronstein, Esq. 或他的法律文员兼客户关系经理、Bronstein、Gewirtz & Grossman, LLC的耶尔·纳森森联系。如果您在Veru遭受损失，则必须在2023年2月6日之前要求法院任命您为首席原告。您无需担任首席原告即可分担任何追回款项。
Bronstein, Gewirtz & Grossman, LLC represents investors in securities fraud class actions and shareholder derivative suits. The firm has recovered hundreds of millions of dollars for investors nationwide. Attorney advertising. Prior results do not guarantee similar outcomes.
Bronstein、Gewirtz & Grossman, LLC在证券欺诈集体诉讼和股东衍生诉讼中代表投资者。该公司已为全国投资者追回了数亿美元。律师广告。先前的结果并不能保证类似的结果。
Contact:
Bronstein, Gewirtz & Grossman, LLC
Peretz Bronstein or Yael Nathanson
212-697-6484 | info@bgandg.com
联系人：
Bronstein、Gewirtz & Grossman, LLC
Peretz Bronstein 或 Yael Nathanson
212-697-6484 | info@bgandg.com
To view the source version of this press release, please visit
要查看本新闻稿的源版本，请访问